NASDAQ:RGLS

Delisted

Regulus Therapeutics Stock News

Healthcare > Biotechnology

Buy RGLS

*Your capital is at risk

$8.16

+0 (+0%)

At Close: Sep 24, 2025

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease

12:59pm, Thursday, 27'th Mar 2025

Regulus Therapeutics Inc. RGLS released topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen (RGLS8429) autosomal dominant polycystic kidney disease (ADPKD

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

07:00am, Thursday, 27'th Mar 2025

Positive Topline Data from the Fourth Cohort of Patients Consistent demonstration of polycystin (PC) biomarker impact confirming 300 mg fixed dose selection to achieve optimal kidney exposure Patien

4 Best Stocks To Buy Under $5

08:36am, Thursday, 20'th Mar 2025

If you're one of the over 4 Million Americans set to retire this year, you may want to pay attention.

What Makes Regulus (RGLS) a New Buy Stock

01:06pm, Wednesday, 19'th Mar 2025

Regulus (RGLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

04:05pm, Thursday, 13'th Mar 2025

Positive topline results from an interim analysis of the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of farabursen (RGLS8429) for the treatment of autosomal

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference

08:00am, Tuesday, 04'th Mar 2025

SAN DIEGO , March 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

08:00am, Tuesday, 04'th Feb 2025

SAN DIEGO , Feb. 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

07:00am, Wednesday, 29'th Jan 2025

Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose response Exploratory results of imaging-based

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

08:00am, Tuesday, 26'th Nov 2024

SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

04:05pm, Thursday, 07'th Nov 2024

Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Presented a

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

08:00am, Tuesday, 08'th Oct 2024

SAN DIEGO , Oct. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by